Retrospective observational study on the effect of vedolizumab treatment on patients with inflammatory bowel disease and extraintestinal manifestations. The EMOTIVE study

First published 11/10/2018

Last updated 23/04/2024

EU PAS number:

EUPAS25761

Study

Finalised

Documents

Study protocol

Study results

Vedolizumab-5041 CSR Synopsis BV 06Apr2022_Redacted Final

English (1.48 MB - PDF)View document

Vedolizumab-5041-Synopsis-08Apr2021

English (668.71 KB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs